(Q38973191)

https://doi.org/10.1007/s00280-020-04166-1

8 September 2017

1 reference

29 December 2023

title

Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level (English)

1 reference

8 September 2017

Anjing Gong

1

1 reference

8 September 2017

Na Ge

2

1 reference

8 September 2017

Weicheng Yao

3

1 reference

8 September 2017

Luxiang Lu

4

1 reference

8 September 2017

Hui Liang

5

1 reference

8 September 2017

publication date

22 July 2014

1 reference

Cancer Chemotherapy and Pharmacology

8 September 2017

published in

1 reference

8 September 2017

volume

74

1 reference

8 September 2017

issue

3

1 reference

8 September 2017

page(s)

531-538

1 reference

Clinical trial end points for high-grade glioma: the evolving landscape.

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

Molecular mechanisms of temozolomide resistance in glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

Saponins: the potential chemotherapeutic agents in pursuing new anti-glioblastoma drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

Pharmacotherapeutic management of pediatric gliomas : current and upcoming strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

The strategy for enhancing temozolomide against malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-014-2534-5

Protective effect of Aplysin on hepatic injury in ethanol-treated rats

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1007/S00280-014-2534-5

Treating malignant glioma in Chinese patients: update on temozolomide

1 reference

30 December 2023

https://opencitations.net/index/api/v1/references/10.1007/S00280-014-2534-5

Identifiers

DOI

10.1007/S00280-014-2534-5

1 reference

Dimensions Publication ID

8 September 2017

1012574742

0 references

1 reference